comparemela.com

Latest Breaking News On - Zoetis stock exchange - Page 1 : comparemela.com

Zoetis Releases 2022 Sustainability Report to Share Progress in Building a Better Future for People, Animals and the Planet

$7.4 million in corporate giving invested in communities, and an additional $5.7 million distributed through Zoetis Foundation grants to support veterinarians and farmers Continued progress. | June 15, 2023

New zealandJeannette ferran astorgaUnited nation sustainable development goals sdgsCorporate affairsUnited nationsMelinda gates foundationInnovation in animal healthZoetis foundationZoetis servicesAnimal healthHealth advancementAre makingUnited nation sustainable development goalsSustainability accounting standards boardClimate related financial disclosureExecutive vice president

Zoetis : One can take advantage of the trading range to enter new positions

Zoetis shares have been fluctuating horizontalally for several weeks. As the share price approaches the lower bounds, a buying opportunity could arise. | May 26, 2023

Zoetis stock exchangePress releaseOuld zts us98978v1035

Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade

Zoetis Inc. is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D. | May 25, 2023

Wetteny josephKristin peckZoetis incNew york stock exchangeAnimal healthAnimal health for the next decadeYork stock exchangeResearch development robert polzerShapes animal healthChief executive officer kristin peckChief financial officer wetteny josephDevelopment robert polzerChief executive officerValue creationReturn on invested capitalChief financial officer

Zoetis Declares Third Quarter 2023 Dividend

The Board of Directors of Zoetis Inc. has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of. | May 11, 2023

Board of directors zoetis incLooking statementsAnnual reportFactors that may affect futureQuarterly reportsCurrent reportsZoetis stock exchangePress releaseEcord zts us98978v1035

Zoetis Announces U S FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Librela™ is the first and only injectable monoclonal antibody treatment for the control of canine OA pain approved in the United States Zoetis continues to advance innovation with a new. | May 5, 2023

New zealandUnited kingdomUnited statesDuncan lascellesLaura olsenAnaesth analgZoetis incCarolina state universityDrug administrationGlobal pain councilAnimal health market analysisPettrak us pain factored nationalEuropean medicines agencyZoetis servicesProfessor of translational research in painUnmet need

vimarsana © 2020. All Rights Reserved.